Pharvaris N.V. (NASDAQ:PHVS) reported on September 8 that once-daily deucrictibant extended-release tablets reduced hereditary angioedema attack rates by 83% relative to placebo in the Phase 3 CHAPTER-3 trial. The result was statistically significant, with a 95% confidence interval of 72% to 90% and a p-value below 0.0001.
The global, double-blind study randomized 85 participants to 40 milligrams of deucrictibant daily or placebo for 24 weeks. The primary endpoint measured investigator-confirmed attacks per four weeks. All secondary efficacy endpoints also achieved statistical significance under a procedure controlling for multiple comparisons.
Pharvaris N.V. plans to submit a prevention New Drug Application to the U.S. Food and Drug Administration in the first half of 2027. The investment question is whether strong attack prevention and oral dosing can win patients in an increasingly competitive category.
Bull Case
The results give Pharvaris N.V. a substantial clinical foundation for its filing. A descriptive analysis showed attack-rate reductions within the first week that were sustained throughout treatment. Secondary endpoints covered clinically relevant outcomes, including attacks requiring on-demand medication, moderate or severe attacks, attack-free status, and disease-specific quality of life.
Deucrictibant targets the bradykinin B2 receptor, aiming to block signaling that drives swelling. Its extended-release formulation is designed to sustain exposure with one daily tablet. If approved, it could appeal to patients who want effective prevention while avoiding injections.
The commercial opportunity extends to people dissatisfied with their current treatment burden. An oral option with sustained disease control could encourage preventive-treatment adoption and support continued use. Those benefits remain commercial possibilities; CHAPTER-3 did not establish better real-world adherence than competing therapies.
Safety findings also support further development. No treatment-related serious adverse events were reported, and one participant in each group discontinued treatment because of an adverse event.
Bear Case
The CHAPTER-3 population was small. Only 55 participants received deucrictibant, compared with 30 receiving placebo. Five participants had HAE with normal C1 inhibitor, limiting conclusions for that subgroup. Among the 80 participants with Type 1 or Type 2 HAE, an additional analysis showed an 87% attack-rate reduction, but that analysis was not adjusted for multiple comparisons.
The safety detail also deserves attention. Treatment-emergent adverse events occurred in 76.4% of deucrictibant recipients versus 56.7% receiving placebo. Investigator-assessed treatment-related events occurred in 20.0% versus 10.0%. One serious adverse event occurred with deucrictibant and was judged unrelated to treatment. The ongoing CHAPTER-4 extension should provide more information about longer-term use.
Oral dosing alone will not establish differentiation. Orladeyo already offers once-daily oral prevention, while Andembry provides once-monthly injections. Some patients may prefer infrequent injections to taking medication every day.
CHAPTER-3 compared deucrictibant with placebo, so it cannot establish superiority or equivalence to either alternative. Pharvaris N.V. must still secure regulatory approval and persuade physicians, patients and insurers that its combination of efficacy, tolerability, and convenience warrants adoption. Coverage restrictions and negotiated discounts could limit commercial returns.
Hedge Fund Sentiment
The filings available so far reflect positions held before Pharvaris N.V. reported its CHAPTER-3 results. Insider Monkey’s database showed 41 hedge funds holding Pharvaris N.V. at the end of 2Q2026, up from 36 funds three months earlier.
Conclusion
Pharvaris N.V. has strengthened its prevention program with a convincing placebo-controlled result. Commercial value will depend on regulatory acceptance, longer-term safety, and evidence that patients choose and continue treatment at reimbursed prices that support attractive returns. The planned filing is the next milestone; oral convenience becomes valuable when it produces sustained adoption.
READ NEXT: Guidewire (GWRE) Grew Fiscal 2026 ARR 19%. Can Cloud Economics Offset Slower Near-Term Growth? and Asana (ASAN) Reached a 10% Non-GAAP Operating Margin. Can Agentic Products Restore Expansion?
This article is originally published at Insider Monkey.
